A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Study Summary

This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.

Conditions

Chronic Hepatitis D Infection

Interventions / Drugs

Brelovitug 300 mg Brelovitug 900 mg Delayed Treatment with Brelovitug 300mg

View on ClinicalTrials.gov ↗

Sponsor

MIRM

Mirum Pharmaceuticals

Liver Disease

D37/100

Study Details

Enrollment80 participants

Primary Completion—

Lead SponsorMirum Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:21:18.704718+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.